Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Authors

Institutions

Publication Details

Journal
The Lancet
Published
2025-10-23
DOI
https://doi.org/10.1016/s0140-6736(25)01375-3
Citations
35
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
45.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Ildiko Lingvay, A. Michael Lincoff, Helen M. Colhoun, Rafael Bravo et al.
35 citations
The Lancet
Diabetes Treatment and Management
45.32
article

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Ildiko Lingvay, A. Michael Lincoff, Helen M. Colhoun, Rafael Bravo, Chau‐Chung Wu, Signe Stensen, Ferruccio Santini, Benjamin M. Scirica, Jorge Plutzky, Silvio Buscemi, Ole Kleist Jeppesen, Issei Komuro, Peter Weeke, G Kees Hovingh, Steven E. Kahn, Jøran Hjelmesæth, Miguel Urina‐Triana, Donna H. Ryan, Scott S. Emerson, John Deanfield, Robert F. Kushner
article en
35 citations

Abstract

No abstract available for this paper.
The LancetVol. 406(10516)
Pennington Biomedical Research Center (US), University of Pisa (IT), Northwestern University (US), Brigham and Women's Hospital (US), Harvard University (US), Novo Nordisk (Denmark) (DK), University of Washington (US), Sykehuset i Vestfold (NO), Cleveland Clinic Lerner College of Medicine (US), VA Puget Sound Health Care System (US), Southwestern Medical Center (US), National Taiwan University Hospital (TW), Universidad Simón Bolívar (CO), The London College (GB), Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT), Institute of Genetics and Cancer (GB), Thrombolysis in Myocardial Infarction Study Group (US), University College London (GB), International University of Health and Welfare (JP), The University of Texas Southwestern Medical Center (US), University of Palermo (IT), University of Edinburgh (GB)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Brigham and Women's Hospital, CSL Behring, Regeneron Pharmaceuticals, TG Therapeutics, Sarnoff Cardiovascular Research Foundation, Novavax, MannKind Corporation, Kowa Company, Mylan, BeiGene, Boehringer Ingelheim Japan, Amryt Pharma, Toa Eiyo, Moderna, Insmed, Diabetes UK, European Commission, Novo Nordisk, Shionogi, Servier, Ono Pharmaceutical, H. Lundbeck A/S, Ipsen, Idorsia Pharmaceuticals, Esperion Therapeutics, Medical Research Council, Daiichi Sankyo Europe
Openalex Percentile: Top 0%
Diabetes Treatment and Management
45.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.